Rhythm Pharmaceuticals Inc. RYTM
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Rhythm Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases, particularly those involving hyperphagia and severe obesity. Its lead product, IMCIVREE (setmelanotide), is a precision medicine targeting rare melanocortin-4…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees283
TickerRYTM
Statistics
Market Cap$6.54B
Revenue (TTM)$189.8M
Net Income-$196.5M
Net Margin-103.6%
EPS$-3.11
P/E-28.44
P/S27.69
P/B48.81
EV/EBITDA-29.36
ROE-101.2%
Dividend Yield—
Price$95.60
Data: Twelve Data · Revenue = mcap / P/S